ABNOM
☆ Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
References
Q-switched Nd:YAG laserrak Ota-ko nevus eta antzeko baldintzak eraginkortasunez tratatzen dituela ezaguna da. Azterketa bat egin dugu high-fluence 1064 nm Q-switched Nd:YAG laser batek nola funtzionatzen zuen Mongoliako lekuetan ezohiko eremuetan, azala argitu gabe. Puntu horiek dituzten 61 paziente aztertu ditugu, guztira 70 lesio aztertuz. Lesioen erdiak laser bidez tratatu ziren, beste batzuk, berriz, konparaziorako tratatu gabe. Melanina maila neurtzeko Mexameter® izeneko eskala eta gailu baten bidez ebaluatu ditugu emaitzak. Pazienteei batez beste 14 hilabetez jarraitu zitzaien tratamendu taldean eta 18 hilabetez behaketa taldean. Azterketaren amaieran, desberdintasun esanguratsuak aurkitu ditugu eskalan puntuazioetan eta melanina-mailetan tratatutako eta tratatu gabeko taldeen artean, laser bidez tratatutako taldeak emaitza hobeak erakusten zituelarik. High-fluence Q-switched Nd:YAG laserra, larruazala argitu gabe, eraginkorra eta segurua izan zen Mongoliako ezohiko leku hauek tratatzeko.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Laser tratamendu espezifiko bat erabiltzearen eraginkortasuna eta segurtasuna aztertu dugu ABNOM -rako, eta zer faktorek eragin dezaketen nola funtzionatzen duten aztertu dugu. ABNOM zuten 110 paziente eta bi eta bederatzi laser tratamendu artean jaso zituzten. Tratamenduak zenbat eta luzeago egin zuen hobeto funtzionatzen zuela ikusi genuen, baina ez bezain ondo gaixo adinekoengan. Larruazal argiagoa (III mota) eta kaltetutako eremu txikiagoak (10 cm2 baino gutxiago) dituzten pazienteetan ere hobeto funtzionatu zuen. ABNOM -rekin batera melasma izateak tratamendua eraginkortasun txikiagoa izan zuen. Eragindako eremuen koloreak edo kopuruak ez omen zuen alderik eragiten. Pazienteen % 10 inguruk puntu ilunagoak izan zituzten tratamenduaren ondoren. Tratamendu anitz goiztiarrak emaitza onak eman zituen. Larruazal ilunagoa eta orban ilunagoak dituzten paziente zaharragoek tratamenduaren ondoren puntu ilunagoak izateko probabilitate handiagoa dute. ABNOM eta melasma duten pazienteentzat, hobe da energia baxuko laser bat erabiltzea, melasma okerrago ez dadin.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Tratamendua
Agente zuritzaileak oso gutxitan laguntzen dute. Melasma ez bezala, ABNOM laser tratamenduarekin hobetu daiteke eta errepikatu gabe kentzeko utzi. Laser tratamendua 10 eta 20 aldiz egin daiteke ABNOM tratatzeko.
#QS1064 laser